| Literature DB >> 35719169 |
Shiwei Li1,2, Yingna Wang1, Weipeng Dun1, Wanqing Han1, Tao Ning3, Qi Sun4, Zichao Wang3.
Abstract
Researchers have investigated the role of polysaccharides in disease treatment via gut microbiota regulation but ignore their function in disease prevention and physique enhancement. In this work, a Gynostemma pentaphyllum polysaccharide (GPP) was tested by methyl thiazolyl tetrazolium (MTT) assay and proved to be safe to Caco-2 cells. Animal experiments showed that the administration of GPP for 3 weeks decreased the body weight gain of mice from 15.4 ± 1.7 to 12.2 ± 1.8 g in a concentration-dependent manner. Analysis of short-chain fatty acids (SCFAs) indicated that GPP increased the levels of acetate, propionate, butyrate, and total SCFAs in the cecum contents of normal mice. Furthermore, GPP improved the species richness and abundance in the gut microbiota but reduced the Firmicutes/Bacteroidetes ratio from 0.8021 to 0.3873. This work provides a basis for incorporating GPP into diet to prevent or mitigate the occurrence of obesity via gut microbiota regulation.Entities:
Keywords: Gynostemma pentaphyllum; body weight; gut microbiota; mice; polysaccharide
Year: 2022 PMID: 35719169 PMCID: PMC9199513 DOI: 10.3389/fnut.2022.916425
Source DB: PubMed Journal: Front Nutr ISSN: 2296-861X
Figure 1Toxicity of GPP to Caco-2 cells by MTT assay. Data are expressed as mean ± SD (n = 3). Significance was determined through ANOVA, *P < 0.05, **P < 0.01.
Influence of GPP on body weight of mice.
|
|
|
|
|
|
|---|---|---|---|---|
| 0 day (g) | 19.3 ± 1.3a | 19.8 ± 1.2a | 20.1 ± 1.8a | 19.5 ± 2.2a |
| 7 day (g) | 24.0 ± 2.1b | 24.5 ± 1.9b | 25.2 ± 1.6b | 24.4 ± 2.1b |
| 14 day (g) | 28.2 ± 1.9c | 28.1 ± 1.8c | 28.5 ± 1.5c | 27.6 ± 1.7c |
| 21 day (g) | 31.7 ± 2.0d | 31.3 ± 1.6d | 31.2 ± 1.8d | 30.1 ± 1.5d |
| 28 day (g) | 34.7 ± 1.8e | 34.1 ± 2.1e | 33.8 ± 2.0e | 31.7 ± 1.9d |
| Weight gain (g) | 15.4 ± 1.7a | 14.3 ± 1.9b | 13.7 ± 1.6b | 12.2 ± 1.8c |
CON, control group; LOW, 100 μg/ml GPP; MID, 400 μg/ml GPP; HIG, 800 μg/ml GPP. Data are expressed as mean ± SD (n = 6). Different letters represent significant differences, P < 0.05.
Figure 2Influence of GPP on acetate, propionate, butyrate, and total SCFAs. (A) Acetate, (B) propionate, (C) butyrate, and (D) total SCFAs. CON: control group, LOW: 100 μg/ml GPP, MID: 400 μg/ml GPP, HIG: 800 μg/ml GPP. Data are expressed as mean ± SD (n = 6). Significance was determined through ANOVA, *P < 0.05, **P < 0.01.
Influence of GPP on the α-diversity of gut microbiota.
|
|
|
| ||
|---|---|---|---|---|
|
|
|
|
| |
| CON | 1,970 ± 163a | 2,018 ± 174a | 6.58 ± 0.42a | 0.98 ± 0.005a |
| LOW | 2,116 ± 203b | 2,209 ± 195b | 7.39 ± 0.35b | 0.97 ± 0.003a |
| MID | 2,289 ± 314c | 2,278 ± 269b | 7.54 ± 0.51b | 0.97 ± 0.003a |
| HIG | 2,536 ± 295d | 2,641 ± 357c | 8.26 ± 0.48c | 0.95 ± 0.002a |
CON, control group; LOW, 100 μg/ml GPP; MID, 400 μg/ml GPP; HIG, 800 μg/ml GPP. Data are expressed as mean ± SD (n = 6). Different letters represent significant differences, P < 0.05.
Figure 3Venn diagram of the gut microbiota among different groups.
Figure 4Relative abundance of the gut microbiota at phylum level.